BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1106 related articles for article (PubMed ID: 26769228)

  • 21. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
    Stone R; Sekeres M; Garcia-Manero G; Lyons RM
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome.
    Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Lee WS; Joo YD
    Eur J Haematol; 2015 Jun; 94(6):546-53. PubMed ID: 25315896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
    N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
    Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
    Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving treatment options of myelodysplastic syndromes.
    Verbeek W; Ganser A
    Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
    Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
    Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
    Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
    Klepfish A; Silbershatz I; Lugassy G; Shimoni A; Mittelman M
    Harefuah; 2013 Oct; 152(10):591-4, 624. PubMed ID: 24450031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do somatic mutations in de novo MDS predict for response to treatment?
    Schroeder MA; DeZern AE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():317-28. PubMed ID: 26637739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonal cytopenias of undetermined significance: potential predictor of myeloid malignancies?
    Vobugari N; Heuston C; Lai C
    Clin Adv Hematol Oncol; 2022 Jun; 20(6):375-383. PubMed ID: 35731608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.